New market access director for Takeda UK

Peter Wheatley Price is to take up the role of market access director at Takeda UK, moving from a senior global role at GSK.

He succeeds Ross Selby, who has moved to the US as Takeda’s new head of global pricing, market access and health economics (oncology). Peter will report directly to Adam Zaeske, UK managing director, and sits on the senior leadership team.

Takeda is currently moving its global business model into being what it calls “an agile speciality care provider” led by the company’s headquarters in Japan.

[caption id="attachment_23782" align="alignnone" width="120"] Peter Wheatley Price[/caption]

The UK company say it has a number of innovative products either in market or approaching launch, and a key part of Peter Wheatley Price’s role will be to ensure patients and the NHS can benefit as much as possible from its treatments.

He will oversee market access, reimbursement and pricing for the whole of the portfolio especially focusing on Takeda’s key therapy areas of IBD, diabetes and oncology.

Peter joins Takeda from GlaxoSmithKline, where he was a global market access and pricing director leading the successful launch of its first respiratory biologic for severe asthma.